List of Camzyos drug patents

Camzyos is owned by Bristol.

Camzyos contains Mavacamten.

Camzyos has a total of 2 drug patents out of which 0 drug patents have expired.

Camzyos was authorised for market use on 28 April, 2022.

Camzyos is available in capsule;oral dosage forms.

Camzyos can be used as treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms.

Drug patent challenges can be filed against Camzyos from 2026-04-28.

The generics of Camzyos are possible to be released after 19 June, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2029
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

12

United States

4

Australia

3

Korea, Republic of

3

Japan

3

Israel

2

Singapore

2

China

2

EA

2

European Union

1

Portugal

1

Malaysia

1

Guatemala

1

Spain

1

Brazil

1

Croatia

1

Costa Rica

1

New Zealand

1

Dominican Republic

1

Philippines

1

Mexico

1

Morocco

1

Peru

1

Hong Kong

1

Tunisia

1

South Africa

1

Lithuania

1

Canada

1

Hungary

1

Slovenia

1

Ukraine

1

Poland

1

Chile

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in